{"id":41550,"date":"2025-09-25T15:03:54","date_gmt":"2025-09-25T09:33:54","guid":{"rendered":"https:\/\/dailynewsindia.co.in\/index.php\/2025\/09\/25\/hetero-healthcare-and-enzene-launch-perzea-affordable-pertuzumab-biosimilar-expands-breast-cancer-treatment-access-in-india\/"},"modified":"2025-09-25T15:03:54","modified_gmt":"2025-09-25T09:33:54","slug":"hetero-healthcare-and-enzene-launch-perzea-affordable-pertuzumab-biosimilar-expands-breast-cancer-treatment-access-in-india","status":"publish","type":"post","link":"https:\/\/dailynewsindia.co.in\/index.php\/2025\/09\/25\/hetero-healthcare-and-enzene-launch-perzea-affordable-pertuzumab-biosimilar-expands-breast-cancer-treatment-access-in-india\/","title":{"rendered":"Hetero Healthcare and Enzene Launch Perzea: Affordable Pertuzumab Biosimilar Expands Breast Cancer Treatment Access in India"},"content":{"rendered":"
\n

Hyderabad (Telangana) [India], September 25:<\/strong> <\/span>In a landmark initiative to expand\u00a0affordable breast cancer treatment in India<\/strong>, Hetero Healthcare Limited has announced the launch of\u00a0Perzea<\/strong>, its most cost-effective biosimilar of Pertuzumab. Developed through a semi-exclusive collaboration with Enzene Biosciences Limited, this breakthrough aims to reduce the economic barriers faced by thousands of HER2-positive breast cancer patients.<\/p>\n

Bringing Advanced Cancer Care Within Reach<\/strong>
\nPertuzumab, a monoclonal antibody, is globally recognised as a\u00a0HER2-positive breast cancer therapy<\/strong>\u00a0when administered with trastuzumab and chemotherapy. Despite its proven efficacy, the high cost of treatment has restricted access in India. With Perzea, Hetero Healthcare is determined to change this reality, offering patients a therapy that balances global standards of care with local affordability.<\/p>\n

Mr. M. Srinivas Reddy, Managing Director of Hetero Healthcare Limited, commented:
\n\u201cOur focus has always been to make advanced therapies more accessible without compromising on quality. With Perzea, we take a decisive step towards ensuring that no patient is denied life-saving care due to affordability challenges.<\/strong>\u201d<\/p>\n

Commitment to Patient-Centred Healthcare<\/strong>
\nAligned with the Government of India\u2019s mission of equitable healthcare, Perzea strengthens Hetero Healthcare\u2019s legacy of delivering low-cost oncology medicines<\/strong>\u00a0across critical therapeutic areas. For breast cancer patients and their families, this launch provides renewed hope by combining affordability with innovation.<\/p>\n

About Hetero Healthcare<\/strong>
\nHetero Healthcare Limited is among India\u2019s leading pharmaceutical companies, delivering high-quality medicines across oncology, antiretrovirals, and critical care. The company\u2019s focus on patient-centric innovation continues to drive better outcomes across India. Learn more: www.heterohealthcare.com<\/a><\/p>\n

About Enzene Biosciences<\/strong>
\nEnzene is a fully integrated biologics innovator with its patented EnzeneX\"\u2122\" continuous manufacturing technology. Operating from Pune (India) and New Jersey (USA), Enzene is transforming biologics production efficiency and affordability. Learn more: www.enzene.com<\/a><\/p>\n

Disclaimer:<\/strong> This article is for general information purposes only and should not be construed as professional medical advice. Always consult your doctor before taking any step.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Hyderabad (Telangana) [India], September 25: In a landmark initiative to expand\u00a0affordable breast cancer treatment in India, Hetero Healthcare Limited has announced the launch of\u00a0Perzea, its most cost-effective biosimilar of Pertuzumab. Developed through a semi-exclusive collaboration with Enzene Biosciences Limited, this breakthrough aims to reduce the economic barriers faced by thousands of HER2-positive breast cancer patients….<\/p>\n

Read More “Hetero Healthcare and Enzene Launch Perzea: Affordable Pertuzumab Biosimilar Expands Breast Cancer Treatment Access in India”<\/span> »<\/a><\/p>\n","protected":false},"author":1,"featured_media":41551,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[639],"class_list":["post-41550","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-health"],"_links":{"self":[{"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/posts\/41550","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/comments?post=41550"}],"version-history":[{"count":0,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/posts\/41550\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/media\/41551"}],"wp:attachment":[{"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/media?parent=41550"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/categories?post=41550"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/tags?post=41550"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}